Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations.

2 Furthermore, recently presented preliminary results from 72 months of follow-up showed a trend of increased overall survival (OS), although it was not statistically significant. 14 The iLLUMINATE study found that the Bruton tyrosine kinase inhibitors ibrutinib in combination with obinutuzumab was associated with improved PFS compared with conventional CIT with ClbO. 10 , 11 , 12 , 13 Oral ad

also in 53,322 other papers